Aevi Genomic Medicine, Inc. GNMX Cash Flow

Aevi genomic medicine, inc. (GNMX)

CashFlow / Quarterly

Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
-4,042	-3,645	-4,839	-6,626	-7,249	-8,191	-8,709	-7,159	-8,605	-8,033	-10,917	-8,483	-10,570	-11,707	-11,144	-6,463	-16,521	-6,086	-8,922	-6,196	-3,040	-3,840	-5,357	-5,208	-6,143	-2,099	-3,679	-2,386	-3,027	-6,946	-2,712	-2,011	-3,424	-2,323	-338
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation
0	3	16	16	17	16	16	16	15	40	41	38	105	67	58	59	57	81	43	63	64	54	44	47	46	45	39	37	36	37	35	33	29	19	17
Loss from disposal of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Stock-based compensation
253	256	628	805	750	786	749	718	875	774	1,001	601	1,924	1,863	2,400	1,550	1,798	2,723	3,117	1,319	1,361	1,758	1,764	-	-	-	-	-	-	-	-	-	-	-	-
Changes in fair value of warrants classified as a liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1,120	-824	1,074	-11	-880	196	110	-	-	-	-	-	-	-	-	-	-	-	-
Accrued severance pay, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	166	89	-5	19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued severance pay, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	86	-	113	-23	47
Exchange differences on a restricted lease deposit and on long term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	21	-22	3	2	-1	1	-8	3	0	1
Loss from disposal of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0
Issuance of shares as consideration for providing security for letter of credit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Stock-based compensation related to options, warrants, common shares and restricted shares granted to employees, directors and consultants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,455	-	285	1,770	177	88	96	123	88
Interest and amortization of beneficial conversion feature of convertible note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Change in fair value of convertible debentures and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	914	-	85	-2,921	-796	654	-197	-206	1,685
Accrued severance pay, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-178	-147	-	-423	3	-9	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
-169	-78	480	-368	-317	54	-92	-61	-121	94	646	-254	-506	308	40	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	245	-	146	103	-10	-338	141	27	91
Restricted lease deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-11	3	0	5	-10	0	1	4	-	-	-	-
Accounts receivable and prepaid expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,278	-	-487	365	430	-807	-809	1,223	33	-40	-1,083	-147	727	-	-	-	-
Exchange differences on a long-term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Decrease (increase) in accounts receivable and prepaid expenses and deferred issuance expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	272	-655	26
Exchange differences on a restricted lease deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	0	1
Exchange differences on a long term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Trade payables
-179	-434	-846	-3	122	-222	742	-2,538	1,600	-919	2,663	-481	115	-838	19	-109	689	255	-589	524	-436	109	-183	-484	645	-50	74	107	-148	21	-6	-25	663	-149	275
Other accounts payable and accrued expenses
743	231	393	-2,087	1,370	426	-143	603	-442	386	-2,796	574	1,583	1,103	-400	-5,948	6,690	851	-1,569	190	645	-435	210	-	-	-	-	-	-	-	-	-	-	-	-
Restricted lease deposits
-	-	-	-	-	-	-	-	-	-	-	-19	-4	10	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long term assets
0	0	0	0	0	-33	-10	43	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-9,830	-9,108	-	-5,242	-3,493	-8,143	-3,605	-1,911	-2,690	-3,989	-4,377	-2,171	-3,379	-2,805	-	-	-	-	-	-	-	-
Net cash used in operating activities
-3,056	-3,511	-5,128	-7,527	-4,673	-7,206	-7,243	-8,342	-6,404	-7,846	-10,654	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,534	-1,978	-2,362	-	-2,460	-1,465	-1,532
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment
-	-	0	-	-	-	0	-	-	0	0	-39	70	126	64	74	13	82	18	75	56	209	24	27	17	105	37	9	9	9	36	39	79	126	45
Proceeds from disposal of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-126	-64	-	-13	-82	-18	-74	-56	-209	-24	-24	-17	-105	-37	-	-	-	-	-	-	-	-
Increase in restricted lease deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	0
Net cash provided by (used in) investing activities
0	0	0	0	0	0	0	-4	152	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4	-10	-40	-	-86	-128	-45
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	28,861	-	-	-	-	-	-	-	-
Proceeds from issuance of shares and warrants, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	8,407	0	-	-	-	-
Deferred issuance expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Proceeds from issuance of shares and warrants, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from exercise of options and warrants
0	0	0	0	0	0	34	0	0	0	19	19	90	72	0	0	968	428	32	15	278	187	764	0	0	0	13	186	1,497	28	0	25	0	0	38
Repayment of a long-term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Proceeds from long-term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Issuance of a convertible debenture and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	19,750	0	-	968	428	32	22,261	244	187	764	0	0	0	28,874	-	-	-	-	-	-	-	-
Increase in short-term bank credit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26
Net cash provided by financing activities
2,000	0	0	1	5,124	-163	34	27,115	-145	0	19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,497	8,435	0	-	0	10,363	64
Decrease in cash and cash equivalents
-	-	-5,128	-	-	-	-7,209	18,769	-6,397	-7,846	-10,635	-7,419	-6,429	9,794	-9,172	35,339	-4,287	-3,147	-8,129	18,582	-1,723	-2,712	-3,249	-4,401	-2,188	-3,484	26,032	-2,568	-41	6,447	-2,402	-2,575	-2,546	8,770	-1,513
Interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	14	35
Cash paid during the period for taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8	6	4	1	4	2	1	5	12	0	-41	46	10	9	21	10	0	1	0	0
Receivables resulting from the exercise of options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	28	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance expenses paid with shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	0	0	0	0	0	0
Issuance of Common stock upon conversion of a convertible debentures
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	8	0	5,577	0
Issuance of Common stock and warrants to consultants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	604	0	0
Classification of liability in respect of warrants into equity due to the exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	145	649	89	0	297	0	101	733